【摘要】 目的:观察拉米夫定治疗活动性肝炎肝硬化的近期疗效。方法:观察组在基础护肝下加用拉米夫定(100mg/d)治疗。对照组仅基础护肝、对症,均治疗1年,观察治疗前后患者症状、体征、肝功能和乙肝病毒复制指标。结果:观察组症状、体征、肝功能显著改善,HBeAg、HBVDNA阴转率显著高于对照组。结论:拉米夫定治疗活动性肝炎肝硬化的近期疗效明显、安全,未见明显不良反应。更多还原

【Abstract】 Objective:To observe Lamivudine’s recent healing effect of curing the active hepatitis and hepatocirrhosis.Methods: To observe the treatment of 48 patients by using more Lamivudine(100mg/d) under the basic liver protection.All of the matched groups are only based on basic liver protection and all are cured for a year,then observe the patients’ symptom,physical sign,liver function and virus duplicate index of hepatitis B before and after the treatment.Results: Observation groups’ symptom,physical sign and liver function improved greatly.The negative conversion rates of HBeAg and HBVDNA are higher than matched groups.Conclusion: Lamivudine’s treatment of active hepatitis and hepatocirrhosis is very good,safe and no adverse reaction.更多还原